Trial Profile
Changes in Bone Turnover With Increased Incretin Hormone Exposure (UAB Diabetes Research and Training Center Pilot and Feasibility Study).
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DRTC
- 02 May 2017 Status changed from recruiting to discontinued.
- 31 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 31 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017.